|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date12 Sep 2013 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date06 Sep 1973 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date07 Dec 1967 |
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease: a Single-group, Non-randomised, Open-label Study (KID-BID)
The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age.
Participants will:
* Take Hydroxycarbamide twice a day every day for 12 months
* Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months
Phase I Trial: RD 785.35736 (ADR-UK-23-1)
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed. ESCORT-HU Extension study aims at evaluating the long-term safety of Siklos® focusing on some questions regarding its safety when used in current practice in adults and paediatric patients treated with Siklos® and followed for up to 5 years. The study will focus on the following concerns : occurrence and incidence of malignancies, leg ulcers, male fertility impairment and serious unexpected AEs causally related to Siklos®.
100 Clinical Results associated with Theravia Pharma SAS
0 Patents (Medical) associated with Theravia Pharma SAS
100 Deals associated with Theravia Pharma SAS
100 Translational Medicine associated with Theravia Pharma SAS